Back to Search
Start Over
Figure S2 from Paclitaxel Plasma Concentration after the First Infusion Predicts Treatment-Limiting Peripheral Neuropathy
- Publication Year :
- 2023
- Publisher :
- American Association for Cancer Research (AACR), 2023.
-
Abstract
- Supplementary Figure 2: Paclitaxel Exposure in Patients Who Did or Did Not Experience Peripheral Neuropathy-Induced Treatment Disruption. Patients who experienced PN-induced treatment disruption had greater median paclitaxel Tc>0.05 than patients who did not (11 hours (IQR 10-15) vs. 9.5 hours (IQR= 9-11), p=0.001) (left panel). The mean Cmax for patients who experienced treatment disruption was not statistically different from those who did not (2591.8 ng/mL (SD 897.9) vs. 2267.4 ng/mL (SD 521.2), p=0.18). The line in the box is the median. The lower and upper hinges correspond to the first and third quartiles and the lines extend 1.5 x IQR, representing an approximate 95% confidence interval.
Details
- Database :
- OpenAIRE
- Accession number :
- edsair.doi.dedup.....3bca13a1e7c23aeff4c603d4b99cf0ff